Phase i study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Chen, Ronald C ^a,b   Rosenman, Julian G ^a,b   Hoffman, Leroy G ^c   Chiu, Wing Keung ^c   Wang, Andrew Z ^a,b   Pruthi, Raj S ^a,b   Wallen, Eric M ^a,b   Crane, Jeffrey M ^b   Kim, William Y ^a,b   Rathmell, W Kimryn ^a,b   Godley, Paul A ^a,b   Whang, Young E ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Chemoradiation; Docetaxel; Intensity modulated radiation therapy; Phase I trial; Prostate cancer

Indexed keywords

DOCETAXEL; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; GONADORELIN; RADIOSENSITIZING AGENT; TAXOID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANDROGEN DEPRIVATION THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE SCINTISCANNING; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DECUBITUS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FAINTNESS; FATIGUE; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INTENSITY MODULATED RADIATION THERAPY; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; URINARY FREQUENCY; URINE RETENTION; UROGENITAL TRACT DISEASE; AGED; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; TAXOIDS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84876437711     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11536.x     Document Type: Article

References (27)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011 ; 61 : 212-36
2. Horwitz EM, Bae K, Hanks GE et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008 ; 26 : 2497-504
3. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005 ; 61 : 1285-90
4. Zapatero A, García-Vicente F, Martín de Vidales C et al. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Int J Radiat Oncol Biol Phys 2011 ; 81 : 1279-85
5. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 ; 351 : 1502-12
6. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 ; 351 : 1513-20
7. Kiura K, Ueoka H, Segawa Y et al. Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 2003 ; 89 : 795-802
8. Varveris H, Mazonakis M, Vlachaki M et al. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyper-fractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck. Oncol Rep 2003 ; 1 0 : 185-95
9. Alvarez EA, Wolfson AH, Pearson JM et al. A phase I study of docetaxel as a radio-sensitizer for locally advanced squamous cell cervical cancer. Gynecol Oncol 2009 ; 113 : 195-9
10. Kumar P, Perrotti M, Weiss R et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol 2004 ; 22 : 1909-15
11. Perrotti M, Doyle T, Kumar P et al. Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol Oncol 2008 ; 26 : 276-80
12. Bolla M, Hannoun-Levi JM, Ferrero JM et al. Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial. Radiother Oncol 2010 ; 97 : 312-7
13. Al-Mamgani A, van Putten WL, Heemsbergen WD et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008 ; 72 : 980-8
14. Kuban DA, Tucker SL, Dong L et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008 ; 70 : 67-74
15. Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005 ; 294 : 1233-9
16. The National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, 2010. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed August 2012
17. Roach M 3rd, Hanks G, Thames H Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006 ; 65 : 965-74
18. Bolla M, Collette L, Van Tienhoven G et al. Ten year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC study. Int J Radiat Oncol Biol Phys 2008 ; 72 : S30-1
19. Bolla M, de Reijke TM, Van Tienhoven G et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009 ; 360 : 2516-27
20. Stinchcombe TE, Bogart JA. Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist 2012 ; 17 : 682-93
21. Khosravi-Shahi P, Cabezón-Gutiérrez L. Selective organ preservation in muscle-invasive bladder cancer: review of the literature. Surg Oncol 2012 ; 21 : e17-22
22. Brizel DM, Lydiatt W, Colevas AD. Controversies in the locoregional management of head and neck cancer. J Natl Compr Canc Netw 2011 ; 9 : 653-62
23. Glynne-Jones R, Kronfli M. Locally advanced rectal cancer: a comparison of management strategies. Drugs 2011 ; 71 : 1153-77
24. Alcantara P, Hanlon A, Buyyounouski MK, Horwitz EM, Pollack A. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 2007 ; 109 : 41-7
25. Lamb DS, Denham JW, Joseph D et al. A comparison of the prognostic value of early PSAtest-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial. Int J Radiat Oncol Biol Phys 2011 ; 79 : 385-91
26. Ray ME, Thames HD, Levy LB et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006 ; 64 : 1140-50
27. Zelefsky MJ, Shi W, Yamada Y et al. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys 2009 ; 75 : 1350-6